肝癌

造模剂
N-Nitrosodiethylamine
Thioacetamide
2-Acetamidofluorene
Aristolochic acid A
抗病毒感染 [1]
HBV
OSS_128167
Emtricitabine
Azvudine
Bicyclol
Morphothiadin
JNJ-632
2',3'-Dideoxyadenosine
Bay 41-4109 racemate
HCV
AG-1478
Mizoribine
Sofosbuvir
Telaprevir
Danoprevir
Boceprevir
Daclatasvir
Lomibuvir
NCCN指南推荐 [2]
一线全身性治疗
Atezolizumab
Bevacizumab
Sorafenib
Lenvatinib
Durvalumab
Pembrolizumab
二线全身性治疗
Regorafenib
Cabozantinib
Ramucirumab
Lenvatinib
Nivolumab
Sorafenib
Ipilimumab
Pembrolizumab
Dostarlimab
FOLFOX4方案
5-FU
Folinic acid
Oxaliplatin
抑制剂
Linifanib
Tivantinib
Axitinib
Apatinib
化疗
铂类
Cisplatin
Carboplatin
Nedaplatin
Oxaliplatin
生物碱类
Paclitaxel
Nab-Paclitaxel
Docetaxel
抗代谢类
Pemetrexed
Gemcitabine
5-FU
Folinic acid
拓扑异构酶抑制剂
Irinotecan
Etoposide
Topotecan
Doxorubicin
Epirubicin HCl
烷化剂
Mitomycin C
Cyclophosphamide
Ifosfamide
TMZ
免疫检查点抑制剂
PD-1
Pembrolizumab
Dostarlimab
Cemiplimab
Camrelizumab
Sintilimab
Nivolumab
Serplulimab
PD-L1
Atezolizumab
Durvalumab
Avelumab
Adebrelimab
Sugemalimab
CTLA-4
Nurulimab
Zalifrelimab
Quavonlimab
Ipilimumab
Tremelimumab
抗血管生成
FGFR
Sorafenib
Ponatinib
Infigratinib
Nintedanib
Fexagratinib
FLT3
Pexidartinib
Crenolanib
Foretinib
UNC2025 HCl
Fedratinib
Src
Src Inhibitor 1
WH-4-023
Saracatinib
Bosutinib
Dasatinib
Syk
R406
R406
PRT062607 HCl
Entospletinib
Piceatannol
靶向突变基因 [3] [4]
Beta-catenin
PRI-724
RCM-1
LF3
Tegatrabetan
MSAB
p53
Nutlin-3a
Pifithrin-α HBr
SAR405838
Eprenetapopt
Pifithrin-μ
MUC16
Sofituzumab vedotin
Oregovomab
Abagovomab
Sofituzumab
FGFR2
NSC12
SKLB 610
Alofanib
Pemigatinib
ASP5878
PBRM1
ACBI1
抗血管生成 (B)
VDA
Verteporfin
Vadimezan
Plinabulin
TIE2
Regorafenib
Tie2 kinase inhibitor 1
Pexmetinib
MGCD-265 analog
Angiotensin
Angiotensin II human Acetate
Angiotensin
Azilsartan
Olmesartan
TKIs
EGFR
Osimertinib
Afatinib
Gefitinib
Lapatinib
Erlotinib
VEGFR
Lenvatinib
Regorafenib
Cabozantinib malate
Axitinib
Lenvatinib Mesylate
c-Met
Cabozantinib
Crizotinib
Capmatinib
Foretinib
SGX-523
PDGFR
Sorafenib
Ponatinib
Sunitinib
Imatinib
Linifanib
c-Kit
Dasatinib
Imatinib
Sorafenib tosylate
Sunitinib
Regorafenib
PI3K/Akt/mTOR
Akt
MK-2206 2HCl
Perifosine
Capivasertib
SC79
GSK690693
PI3K
LY294002
3-MA
Dactolisib
Pictilisib
Wortmannin
mTOR
Rapamycin
Everolimus
Dactolisib
AZD8055
NU7441
AMPK
Nilotinib
GSK690693
Doxorubicin HCl
AICAR
Phenformin HCl
DNA-PK
Nedisertib
T0070907
Samotolisib
Torin 2
PP121
MAPK
Ras
Zoledronic acid
Sotorasib
Lonafarnib
ARS-1620
Zoledronic acid monohydrate
ERK
Bortezomib
SCH772984
Bosutinib
BIX 02189
Resveratrol
Raf
Vemurafenib
Sorafenib
Sorafenib tosylate
Dabrafenib
Regorafenib
MEK
Trametinib
Mirdametinib
U0126-EtOH
Selumetinib
PD98059
JNK
SP600125
Doramapimod
JNK-IN-8
Metformin HCl
Anisomycin
Cell Cycle
Rho
Rhosin hydrochloride
Zoledronic acid
Fasudil HCl
NSC 23766 trihydrochloride
ML141
p21
Dacinostat
APTO-253
Ailanthone
GC7 Sulfate
UC2288
CDK
Palbociclib HCl
Dinaciclib
Ro-3306
Roscovitine
PF-562271
DNA/RNA Synthesis
PF-562271
Cisplatin
Gemcitabine
5-FU
Cycloheximide
Chk
Oxaliplatin
AZD7762
Rabusertib
MK-8776
CHIR-124
Prexasertib HCl
mAb & ADC
EGFR
Cetuximab
Panitumumab
Cetuximab-MMAE
Serclutamab talirine
Laprituximab emtansine
Depatuxizumab mafodotin
Disitamab vedotin
VEGFR
Bevacizumab
Ramucirumab
MUC16
Sofituzumab vedotin
Oregovomab
Abagovomab
Sofituzumab
GPC3
Codrituzumab
Codrituzumab-MMAE
PD-1
Pembrolizumab
Dostarlimab
Cemiplimab
Camrelizumab
Sintilimab
Nivolumab
Serplulimab
PD-L1
Atezolizumab
Durvalumab
Avelumab
Adebrelimab
Sugemalimab
CTLA-4
Nurulimab
Zalifrelimab
Quavonlimab
Ipilimumab
Tremelimumab
相关化合物库
FDA-approved Anticancer Drug Library
Anti-cancer Compound Library
Anti-cancer Compound Library-Ⅱ
Anti-cancer Metabolism Compound Library
Cambridge Cancer Compound Library
Small Molecule Immuno-Oncology Compound Library
Tyrosine Kinase Inhibitor Library
Angiogenesis Related compound Library
MAPK Inhibitor Library
PI3K/Akt Inhibitor Library